Eric Nuermberger

PROFESSOR

19992018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 21 Similar Profiles
Tuberculosis Medicine & Life Sciences
rifapentine Medicine & Life Sciences
Pyrazinamide Medicine & Life Sciences
Rifampin Medicine & Life Sciences
Mycobacterium tuberculosis Medicine & Life Sciences
Multidrug-Resistant Tuberculosis Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
bedaquiline Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2018

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis

Leung-Theung-Long, S., Coupet, C. A., Gouanvic, M., Schmitt, D., Ray, A., Hoffmann, C., Schultz, H., Tyagi, S., Soni, H., Converse, P. J., Arias, L., Kleinpeter, P., Sansas, B., Mdluli, K., Vilaplana, C., Cardona, P. J., Nuermberger, E., Marchand, J. B., Silvestre, N. & Inchauspé, G., May 1 2018, In : PLoS One. 13, 5, e0196815.

Research output: Contribution to journalArticle

Vaccinia
Chemotherapy
Vaccinium
Mycobacterium tuberculosis
Combination Drug Therapy

Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis

Ammerman, N., Swanson, R. V., Bautista, E. M., Almeida, D. V., Saini, V., Omansen, T. F., Guo, H., Chang, Y. S., Li, S. Y., Tapley, A., Tasneen, R., Tyagi, S., Betoudji, F., Moodley, C., Ngcobo, B., Pillay, L., Bester, L. A., Singh, S. D., Chaisson, R. E., Nuermberger, E. & 1 othersGrosset, J. H., Jul 1 2018, In : Antimicrobial Agents and Chemotherapy. 62, 7, e00636-18.

Research output: Contribution to journalArticle

Clofazimine
Tuberculosis
Pharmaceutical Preparations
Therapeutics
Multidrug-Resistant Tuberculosis

Long-acting formulations for the treatment of latent tuberculous infection: Opportunities and challenges

Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., Nuermberger, E., Kim, P., Barry, C. E., Owen, A., Hazuda, D. & Flexner, C. W., Feb 1 2018, In : International Journal of Tuberculosis and Lung Disease. 22, 2, p. 125-132 8 p.

Research output: Contribution to journalReview article

Tuberculosis
Infection
HIV
Drug Compounding
Virus Diseases

New drugs and regimens for tuberculosis

Chang, K. C., Nuermberger, E., Sotgiu, G. & Leung, C. C., Nov 1 2018, In : Respirology. 23, 11, p. 978-990 13 p.

Research output: Contribution to journalReview article

Multidrug-Resistant Tuberculosis
Drug Repositioning
Tuberculosis
Drug Resistance
Pharmaceutical Preparations

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer

Converse, P. J., Almeida, D. V., Tasneen, R., Saini, V., Tyagi, S., Ammerman, N., Li, S. Y., Anders, N., Rudek-Renaut, M., Grosset, J. H. & Nuermberger, E., Aug 1 2018, In : PLoS neglected tropical diseases. 12, 8, e0006728.

Research output: Contribution to journalArticle

Rifamycins
Mycobacterium ulcerans
Buruli Ulcer
Clofazimine
Rifampin